A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Belizatinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors TESARO
- 18 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
- 18 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
- 04 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History